This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: The Annals of Thoracic Surgery
Author(s): Richard D. Mainwaring, William L. Patrick, Ali N. Ibrahimiye, Naruhito Watanabe, George K. Lui, Frank L. Hanley

Mainwaring and colleagues retrospectively reviewed the outcomes for 51 patients with transposition of the great arteries (TGA) who were enrolled in a left ventricle (LV) retraining program in preparation for an arterial switch procedure. Retraining was successful in 52% of patients with D-TGA and 92% of patients with L-TGA. Of patients who had successful retraining and underwent an arterial switch operation, the procedure was successful for 77% of patients with D-TGA and 100% with L-TGA. To quantify the LV response to training, the authors calculated an “LV retraining ratio” based on the change in the LV/RV pressure ratio in response to the first pulmonary artery banding. This ratio correlated with the presence or absence of heart failure and accurately predicted the ultimate success of retraining in 95% of patients.

Source: Interactive Cardiovascular and Thoracic Surgery
Author(s): Daniel JFM Thuijs, Graeme L Hickey, Ruben LJ Osnabrugge

The EJCTS and ICVTS are publishing a series of Statistical Primers to help clinicians perform and interpret research. Although Kaplan-Meier analyses are standard in the cardiothoracic surgical literature, there are several pitfalls that should be kept in mind. In this primer, Thuijs and coauthors describe the fundamental concepts of analyzing survival data.

Source: The Annals of Thoracic Surgery
Author(s): Rishindra M. Reddy, William B. Weir, Shari Barnett, Brendan T. Heiden, Mark B. Orringer, Jules Lin, Andrew C. Chang, Philip W. Carrott, William R. Lynch, David G. Beer, J. Christopher Fenno, Yvonne Kapila

Reddy and colleagues evaluated oral, esophageal, and gastric microbial flora in 55 patients who underwent successful esophagectomy for adenocarcinoma, squamous cell carcinoma, or benign disease. The authors did not observe significant patterns between microbiome diversity and tumor stage or histology. Patients who had anastomotic leak, however, showed a greater variance in the composition of preoperative oral flora versus intraoperative gastric flora than patients who did not (p = 0.015). The authors suggest that better understanding of the relationship between the microbiome and esophagectomy recovery could lead to new predictive or therapeutic approaches for esophageal anastomotic leak.

Source: The New England Journal of Medicine
Author(s): Mandeep R. Mehra, Daniel J. Goldstein, Nir Uriel, Joseph C. Cleveland, Melana Yuzefpolskaya, Christopher Salerno, Mary N. Walsh, Carmelo A. Milano, Chetan B. Patel, Gregory A. Ewald, Akinobu Itoh, David Dean, Arun Krishnamoorthy, William G. Cotts, Antone J. Tatooles, Ulrich P. Jorde, Brian A. Bruckner, Jerry D. Estep, Valluvan Jeevanandam, Gabriel Sayer, Douglas Horstmanshof, James W. Long, Sanjeev Gulati, Eric R. Skipper, John B. O’Connell, Gerald Heatley, Poornima Sood, and Yoshifumi Naka, for the MOMENTUM 3 Investigators

An interesting two-year report from the MOMENTUM 3 randomized controlled trial comparison of HeartMate 3 and II, the analysis performed by Abbott. Although stroke and reoperation were clearly lower with the latest technology, reflected in the lower LDH measurements, there was bafflingly no improvement in survival.


Source: News from around the web.
Author(s): Claire Vernon

Patient Care

Carter Capps, a pitcher for professional baseball team the San Diego Padres, has made himself a necklace out of the rib surgeons removed during his thoracic outlet surgery.

A Connecticut, USA, man gets some experimental and synergistic help from a bacteriophage and antibiotic to treat a persistent infection in his aortic graft.


Drugs and Devices

The US Food and Drug Administration (FDA) has approved the world’s smallest mechanical heart valve for pediatric patients, a 15 mm Masters Series Heart Valve from Abbott.

Durvalumab from AstraZeneca has been approved by the US FDA for patients with unresectable stage III non-small cell lung cancer; this follows the publication of a randomized trial showing superiority of durvalumab over placebo following chemotherapy.


Research, Trials, and Funding

Researchers from Vancouver, Canada, presented their early experience with the Sapien M3, a transcatheter mitral valve replacement device that caught the attention of attendees at the recent Cardiovascular Research Technologies meeting.

The use of lung cancer treatment modalities varies by geographic region across the UK, according to research published in Thorax, and the researchers say this could be negatively affecting patient survival in regions with lower treatment rates.

In Indiana, USA, the first patient has been enrolled in the EVAS2 IDE Confirmatory Clinical Study of the Nellix EndoVascular Aneurysm Sealing System from Endologix.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Ilhan Inci, Ilker Iskender, Jonas Ehrsam, Claudio Caviezel, Sven Hillinger, Isabelle Opitz, Didier Schneiter, Walter Weder

Inci and colleagues reviewed prospectively collected data from 117 patients with end-stage emphysema undergoing lung transplantation. The authors found that short-term and long-term survival were equivalent in patients who did and did not undergo lung volume reduction surgery prior to their transplantation (107 versus 86 months, p = 0.6).

Source: Pediatric Pulmonology
Author(s): Elisabeth Dellon, Samuel B. Goldfarb, Don Hayes Jr, Gregory S. Sawicki, Joanne Wolfe, Debra Boyer

A handy view from the pediatric standpoint on an expanding indication for sequential pulmonary transplanation.

Source: Medical Economics
Author(s): Craig M. Wax

Physicians are at high risk for burnout, physical disability, and financial deprivation after investing time and money in obtaining their training.  This article highlights how physicians can maintain their health and positive outlook to enable them to continue helping others.

Source: The Lancet
Author(s): David L Brown, Rita F Redberg

A few months after its publication, the ORBITA trial results do not seem to have filtered adequately to cardiac multidisciplinary teams worldwide.

Source: Science
Author(s): Seth Thomas Scanlon

This brief synopsis of an article published in Cell describes how certain skin microorganisms interact beneficially with the host to accelerate wound healing.